I'm also proud to report that our operating activities over the first six months generated $4.4 million of cash, and our cash balance at the end of the second quarter increased over 80% since the beginning of this year to $6.8 million. It is validating to see the improving cash-generating capability of our business as our operating performance continues to strengthen. We also made important progress subsequent to quarter end, with respect to our capital structure. As many of you know, we entered into a third amendment and forbearance agreement with Fifth Third Bank. Although our financing discussions have required considerable management attention over the past several months, we believe the agreement provides a defined framework that allows us to remain focused on executing our operating strategy while we continue pursuing longer-term capital solutions. A few months ago, I formed a new company that recently purchased additional shares of our company from a private investor. In addition, this new company has invested $2 million of subordinated financing after quarter end, which reflects our continued confidence in the long-term prospects of the company and provides additional financial flexibility as we move forward. Importantly, none of these financing activities have changed our long-term strategic priorities. In Rhode Island, we continue advancing opportunities created through our Certificate of Need approvals. including plans for a new radiation therapy center in Bristol and a proton beam radiation therapy center in Johnston. Internationally, we remain excited about the continued development of our operations in Latin America and the opportunities we see to further expand our presence in attractive markets. An important component of our international growth strategy is in Guadalajara, Mexico, where we are partnering with Hospital San Javier to upgrade their Gamma Knife Center. Importantly, this is an established Gamma Knife market and a well-established clinical partner. Hospital San Javier has been providing Gamma Knife treatments since 1994, giving us an experienced physician and institutional platform from which to build. While we recognize there's still important work ahead of us, particularly regarding our balance sheet, I remain extremely confident in the underlying strength of our business. Our focus remains squarely on growing patient volumes, expanding and diversifying our installed base of advanced radiation therapy technologies, strengthening our partnerships with leading healthcare systems, and allocating capital where we believe it can generate attractive long-term returns. With that, I'll turn the call over to our interim CEO, Craig Tagawa, who will provide more detail on our operational performance. Greg.

Thank you, Ray, and good afternoon, everyone. I'd also like to thank all of you for joining us today and for your continued interest in American Shared Hospital Services. The second quarter was another quarter of solid operational execution and meaningful progress across our businesses. While our reported financial results include several substantial items that Alexis will discuss in greater detail. I believe the most important takeaway from the quarter is that the underlying business continues to move in the right direction. We generated strong quarterly revenues of approximately $8.4 million, representing 19% year-over-year growth, while first-half revenues increased to more than $15.5 million. Those results were driven by continued growth in our direct patient services segment, improving proton beam radiation therapy performance, and higher procedure volumes across our international Gamma Knife operations. More importantly, we continue to see encouraging trends in the metrics that matter most to the long-term success of our business, patient volumes, utilization, physician engagement, and central-level operating performance. Beginning with Rhode Island, our three radiation oncology centers continued to improve during the quarter. These facilities once again generated strong revenue growth, supported by increased patient procedures and continued operational improvements. Since acquiring these centers, our primary objective has been to strengthen physician relationships, improve operational execution, and expand patient access to high-quality radiation therapy services. We believe we are making meaningful progress against each of those objectives. While there are still additional opportunities ahead, we are encouraged by the trajectory of these operations and believe they represent an important long-term growth platform for the company. Our Puebla, Mexico Radiation Therapy Center also delivered another strong quarter. Patient activity remained healthy, reimbursement trends continue to be favorable, and the operational improvements we've implemented over the past year are translating into better financial performance. Weblook continues to demonstrate the value of our international operating strategy, and we believe it provides a strong foundation for operational opportunities throughout Latin America. Turning to proton beam radiation therapy, our leasing arrangement in Orlando delivered another excellent quarters. Revenues increased over 22 percent year over year as both treatment volumes and reimbursement improved. Photon beam radiation therapy remains an important component of our diversified treatment portfolio and we're pleased with the continued performance of this asset. Our gammonized business also continue to make encouraging progress. While domestic leasing volumes continue to reflect the expiration of one customer agreement last year, we experienced strong growth across our international Gamma Knife Centers. The ESPRI upgrade completed in Peru last year continues to produce operational benefits through shorter treatment times, improved patient throughput, and higher utilization. We believe these improvements demonstrate the value of continuing to invest in next-generation technology across our installed base. As we look across the entire organization, one theme continues to stand out. Utilization. Increasing patient throughput remains the single greatest driver of long-term value creation within our business. Many of our facilities have significant operating leverage. As procedure volumes continue to increase, we expect that incremental revenue will increasingly translate into improved profitability and stronger cash generation. That remains a central focus for our management team. Beyond our current operations, we're also excited about the opportunities ahead. In Rhode Island, we continue to work toward development opportunities associated with our previously approved certificates of need. These projects have the potential to significantly expand our presence in one of our strongest operating markets and represents an important component of our long-term growth strategy. As Ray mentioned earlier, we also made important progress regarding our financing capabilities after quarter end. While much of the public attention has understandably focused on the balance sheet, I believe it's equally important to recognize the progress occurring throughout our operating business. Revenue continues to grow, patient volumes continue to improve, our clinical partners remain strong, and our operating teams continue to execute at a very high level. Taken together, these trends reinforce our confidence that the business is becoming stronger and better positioned for sustainable long-term growth. While there is still work ahead, I believe the progress we're making today lays the foundation for meaningful long-term value for our shareholders. With that, I'll turn the call over to our interim chief financial officer, Alexis Wallace, who will review our financial results in greater detail.

Thank you, Craig. And good afternoon, everyone. As Craig highlighted, the second quarter reflected continued operating momentum across our business. We delivered strong growth in our direct patient services platform, solid improvement in operating cash flow, and continued progress strengthening our liquidity. While reported earnings were affected by several significant items during the quarter, we believe our underlining operating performance continues to improve and provides a solid foundation for future growth. Beginning with revenue, total revenue for the second quarter increased 19.2% to approximately $8.4 million, compared with $7.1 million in the prior year period. For the first six months of 2026, revenue increased 17.7% to approximately $15.5 million from $13.2 million in the first half of 2025. The primary driver of this performance continued to be our direct patient services segment. Second quarter direct patient services segment revenue increased approximately 40% to $4.9 million, while first-half revenue increased 35% to approximately $8.9 million. This growth was driven by primarily higher patient procedure volumes at our Rhode Island radiation oncology centers, together with another strong quarter from our Peru and Pueblo Mexico facilities. Importantly, these centers continue to demonstrate the operating leverage we anticipated when we made these investments. As patient volumes continue to grow, we believe this business will become an increasingly meaningful contributor to both revenue growth and long-term profitability. Within our medical equipment leasing segment, overall revenue remained relatively stable compared with the prior year. While domestic gammonized leasing activity reflected the expiration of one customer agreement during 2025, this was substantially offset by continued strength in our proton beam radiation therapy business. Proton beam radiation therapy revenue increased 22% to approximately $2.3 million during the quarter and approximately $4.3 million for the first six months of the year, benefiting from both higher treatment volumes and improved reimbursement levels. Gemini from the revenue also increased modestly during the quarter as procedure volumes continued recovering at our international treatment centers following completion of the free upgrade in Lima. The improved efficiency of the upgraded platform has enhanced patient throughput and contributed to stronger operating performance across our international operations. Turning to profitability, gross margin for the quarter was approximately $1.4 million. While modestly below last year's level, it improved sequentially from the first quarter of 2026, despite the continued expansion of our direct patient services business, which carries a different cost structure than our traditional equipment leasing operations. We believe this reflects continued operational execution as we scale that business. Adjusted EBITDA for the second quarter was approximately $1.3 million compared with $1.7 million in the prior year quarter. On a year-to-date basis, adjusted EBITDA totaled approximately $2.5 million, reflecting the continued cash-generating strength of our operating platform. Moving further down the income statement, selling and administrative expenses increased year over year, primarily reflecting legal and professional costs of $285,000 associated with negotiating the Third Amendment to our credit agreement. In addition, we recorded a higher allowance for credit losses of $909,000 against Rhode Island receivables prior to May 31st of 2025. As we mentioned in prior calls, we've been focused on improving our accounts receivable and billing systems and have made good progress in that area, so we are well positioned going These two items represented the primary drivers of the increase in our reported net loss during We view both as largely independent of the operating trends within the business. Excluding these items, our core operations continue to perform well, supported by higher patient volumes, improving reimbursement trends, and disciplined operating execution. Another encouraging development with the continued decline in interest expense is our average debt balances decrease, reflecting our ongoing efforts to strengthen our balance sheet. Turning to liquidity, we ended the quarter with approximately $6.8 million in cash, cash equivalents and restricted cash, compared with $3.7 million at year-end of $25. 5. Perhaps most encouraging, operating activities generated $4.4 million of cash during the first six months of the year. This strong cash generation enabled us to fund scheduled debt repayments and distributions to our minority partners while simultaneously increasing our cash position. We believe this demonstrates the improving cash generating capability of our business as operating performance continues to strengthen. Subsequent to quarter N, we completed the previously announced Third Amendment and Forbearance Agreement with the Third Bank. This agreement provides additional flexibility as we continue evaluating longer-term financing alternatives and executing our strategic priorities. Additionally, we completed a $2 million subordinated financing for a newly created company formed by our Executive Chairman. Together, these actions enhance our liquidity, provide additional financial flexibility, and allow management to remain focused on executing our operating strategy while pursuing opportunities to further strengthen our capital structure. Looking ahead, our financial priorities remain clear. First, continuing driving sustainable revenue growth by increasing utilization across our existing treatment network while expanding our installed base of advanced radiation therapy technologies. Second, translate that revenue growth into improved profitability and operating cash flow through discipline, execution, and continued operating efficiency. And third, continue strengthening our balance sheet and capital structure while maintaining the flexibility necessary to support future growth opportunities and create long-term shareholder value. Overall, we are encouraged by the progress achieved during the first half of 2026. The underlying fundamentals of our business continue to improve. Our operating cash flow remains strong. Demand across our treatment platform is healthy, and we believe the company is well-positioned to build on this momentum during the remainder of the year. With that, Nick, you may open up the call for any questions.

Thank you. We will now begin the question and answer session. To ask a question, you may press star, then 1 on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. At this time, we'll pause momentarily to assemble the roster. The first question will come from M. Marin with Zax. Please go ahead.

Thank you. So on the back of the strength of this quarter, I think when you originally went down the path of, you know, growing the direct patient operations, one thing you talked about was having much greater control over.